The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

Abstract Background Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14 months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel multimodal treatment approach we combined the checkpoint kinase 1 (Chk1) in...

Full description

Bibliographic Details
Main Authors: Ina Patties, Sonja Kallendrusch, Lisa Böhme, Eva Kendzia, Henry Oppermann, Frank Gaunitz, Rolf-Dieter Kortmann, Annegret Glasow
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Glioblastoma
Chk1 inhibitor
SAR-020106
Decitabine
Irradiation
Temozolomide
Online Access:http://link.springer.com/article/10.1186/s13046-019-1434-2

Internet

http://link.springer.com/article/10.1186/s13046-019-1434-2

Similar Items